Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia

ConditionsPreeclampsia Preeclampsia (PE)Preeclampsia (PE) Risk Obesity and Obesity-related Medical Conditions Pregnancy Pregnancy Complications Gestational Diabetes Gestational Diabetes Mellitus in Pregnancy Gestational Complications

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18-45

SponsorUniversity of Tennessee Graduate School of Medicine

About this trial

This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.

Eligibility criteria

Qualifiers

Recommended aspirin for pre-eclampsia prevention by OB/GYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)

Willingness to adhere to aspirin therapy

Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.

Gestational age at enrollment <16 weeks

Disqualifiers

Type 2 Diabetes Mellitus

Type 1 Diabetes Mellitus

Current gestational diabetes mellitus

Current/active platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura/ITP, thrombotic thrombocytopenic purpura/TTP, von Willebrand disease, etc.)

Trial design

Treatments tested in this trial

Not listed

Trial groups

50 Participants

are grouped into 1 trial group

Locations

University of Tennessee Medical Center37920, KnoxvilleTennessee, United States

Sponsors and collaborators

University of Tennessee Graduate School of Medicine

Lead sponsor

Source ClinicalTrials.gov